Mesenchymal stem cells and immunomodulation: current status and future prospects
Citations Over TimeTop 1% of 2016 papers
Abstract
The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them an invaluable cell type for the repair of tissue/ organ damage caused by chronic inflammation or autoimmune disorders. Although they hold great promise in the treatment of immune disorders such as graft versus host disease (GvHD) and allergic disorders, there remain many challenges to overcome before their widespread clinical application. An understanding of the biological properties of MSCs will clarify the mechanisms of MSC-based transplantation for immunomodulation. In this review, we summarize the preclinical and clinical studies of MSCs from different adult tissues, discuss the current hurdles to their use and propose the future development of pluripotent stem cell-derived MSCs as an approach to immunomodulation therapy.
Related Papers
- → Generation of Fully Pluripotent Female Murine-Induced Pluripotent Stem Cells1(2015)8 cited
- → Differences in the Gene Expression Profiles of Slow- and Fast-Forming Preinduced Pluripotent Stem Cell Colonies(2015)5 cited
- → Analysis of approaches to increase the efficacy of cell therapy based on mesenchymal stromal cells(2021)2 cited
- → Генерування інсулін-продукуючих клітин зі стовбурових клітин. Перепрограмування соматичних клітин(2022)2 cited
- → Immunomodulatory characterization of an umbilical cord-derived mesenchymal stromal cells (UC-MSCs)-based cell therapy(2021)